Novo Nordisk's obesity drug shows weight loss of up to 14.5% in mid-stage study

() -​Novo Nordisk ‌said on Tuesday ‌its experimental obesity drug, ⁠amycretin,‌ showed statistically significant ‍weight loss of up to ​14.5%‌ at 36 weeks in patients with type 2 ⁠diabetes ​in a ​mid-stage study.

Lilly, Novo Nordisk back direct-to-employer programs to expand access to weight-loss drugs

Eli Lilly said on Friday it plans to roll out an employer-focused obesity care model early next year, aiming to expand access to its blockbuster weight-loss drug through partnerships with third-party firms.

Pharma market shake-up: Bayer jumps, Novo Nordisk sinks 10%

Shares of Danish pharmaceutical giant Novo Nordisk fell sharply after its Alzheimer's drug failed to slow progression of the disease in a trial. Meanwhile, Germany's Bayer said their stroke-prevention drug showed positive results,

Novo Nordisk to offer select doses of Ozempic, Wegovy at a steep discount

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month. Then the monthly cost will rise to $349.
Feedback